
Lipocine Inc has announced results from its phase 2 clinical trial (NCT04134091), which includes results for LPCN 2401, the company’s …
Boyds expands Regulatory Affairs team to support growing demand
Sterling doubles ADC manufacturing capacity at Welsh facility
Femtosecond laser cuts lung tumour margin assessment time
Blood sensor detects Parkinson’s-associated proteins in 40 minutes

